论文部分内容阅读
目的探讨白花蛇舌草水提部位(HD-1)体内外抗肿瘤活性。方法体外实验采用MTT法检测HD-1对人肝癌细胞HepG2、人直结肠癌细胞株HCT-116的生长抑制作用;体内实验采用S180实体瘤小鼠动物模型评价HD-1不同剂量(100,50 mg.kg-1)对S180肉瘤的生长抑制作用及对荷瘤小鼠体重、抑瘤率、胸腺指数、脾指数等的影响。结果 HD-1在体外可显著抑制HepG2、HCT-116肿瘤细胞的增值,其效果与剂量和作用时间相关;体内试验表明,与模型组比较,HD-1高、中剂量组(100,50 mg.kg-1)显著抑制S180肉瘤生长,平均抑制率分别为12.5%和33.1%,脾指数显著升高(P<0.05);环磷酰胺(CTX)联合HD-1中剂量组与CTX(20mg.kg-1)组比较,联合组胸腺指数、脾脏指数、肝指数显著提高(P<0.05),肺指数显著降低(P<0.01)。结论 HD-1在体外能明显抑制HepG2、HCT-116细胞的增值,体内能抑制荷瘤小鼠S180肉瘤生长。
Objective To investigate the anti-tumor activity of Hedyotis diffusa Willd. (HD-1) in vitro and in vivo. Methods MTT assay was used to detect the growth inhibition effect of HD-1 on human hepatocellular carcinoma cell line HepG2 and human colon carcinoma cell line HCT-116. In vivo, S180 solid tumor mouse model was used to evaluate the effects of HD-1 at different doses mg.kg-1) on S180 sarcoma growth inhibition and tumor-bearing mice weight, tumor inhibition rate, thymus index, spleen index and so on. Results HD-1 could significantly inhibit the proliferation of HepG2 and HCT-116 tumor cells in vitro, and its effect was related to dose and duration of action. In vivo experiments showed that compared with model group, HD-1 high and medium dose groups (100 and 50 mg .kg-1) significantly inhibited the growth of S180 sarcoma. The average inhibitory rates were 12.5% and 33.1% respectively, and the spleen index was significantly increased (P <0.05). CTX and HD- (P <0.05). The index of pulmonary index was significantly lower (P <0.01) in the combined group. Conclusion HD-1 can significantly inhibit the proliferation of HepG2 and HCT-116 cells in vitro and inhibit the growth of S180 sarcoma in vivo.